ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 180 filers reported holding ASCENDIS PHARMA A/S in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,250,076 | +104.6% | 24,029 | +95.0% | 0.01% | +125.0% |
| Q2 2023 | $1,099,649 | -16.8% | 12,321 | -0.0% | 0.00% | -33.3% |
| Q1 2023 | $1,321,486 | -12.2% | 12,325 | 0.0% | 0.01% | -25.0% |
| Q4 2022 | $1,505,253 | +917.1% | 12,325 | +673.2% | 0.01% | +700.0% |
| Q2 2022 | $148,000 | +20.3% | 1,594 | +52.4% | 0.00% | 0.0% |
| Q1 2022 | $123,000 | +2975.0% | 1,046 | +3069.7% | 0.00% | – |
| Q4 2021 | $4,000 | -20.0% | 33 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | +25.0% | 33 | 0.0% | 0.00% | – |
| Q2 2021 | $4,000 | 0.0% | 33 | 0.0% | 0.00% | – |
| Q1 2021 | $4,000 | -33.3% | 33 | 0.0% | 0.00% | – |
| Q4 2020 | $6,000 | +20.0% | 33 | 0.0% | 0.00% | – |
| Q3 2020 | $5,000 | – | 33 | +1000.0% | 0.00% | – |
| Q2 2020 | $0 | – | 3 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |